Angioedema, angiotensin converting enzyme inhibitors, and angiotensin receptor blocking drugs [3]

Canadian Journal of Anesthesia

Volumn 54, Issue 2, 2007, Pages 155-157

  Adachi, Yushi U ^a   Iwakiri, Satoko ^a   Katoh, Takasumi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANGIONEUROTIC EDEMA; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; DRUG SAFETY; ENDOTRACHEAL INTUBATION; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

EID: 33947719875     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022016     Document Type: Letter

References (6)

1. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anesth 2006; 53: 994-1003.
2. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15(suppl. 6): S46-56.
3. Pretorius M, McFarlane JA, Vaughan DE, Brown NJ, Murphey LJ. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass. Clin Pharmacol Ther 2004; 76: 379-87.
4. Cugno M, Nussberger J, Biglioli P, Alamanni F, Coppola R, Aqostoni A. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120: 1776-82.
5. Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002; 22: 1173-5.
6. Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother 2003; 37: 1024-7.